To identify whether H19 expression could act as a potential biomarker in the surveillance of AML, we next assessed H19 expression in AML patients of different clinical stages including 54 patients who achieved CR after induction therapy and 26 relapsed patients. This evidence concerns the gene H19 and acute myeloid leukemia.